BridgeBio Pharma Inc. (BBIO) Misses Q4 EPS by 28c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts BBIO Hot Sheet
Join SI Premium – FREE
BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q4 EPS of ($1.00), $0.28 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $154.2 million versus the consensus estimate of $146.16 million.
For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Starts H2O America (HTO) at Outperform
- Kotak Upgrades Muthoot Finance Ltd (MUTH:IN) to Buy (1)
- BofA Securities Reiterates Buy Rating on Reliance Industries (RELIANCE:IN)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
